In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Euthymics Bioscience, Inc.

Latest From Euthymics Bioscience, Inc.

Deal Watch: GSK Makes $85m Wager On Surface’s Preclinical NK Cell Therapy

Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.

Business Strategies Deals

Cytokinetics Sees Omecamtiv Potential In Certain Heart Failure Patients

Detailed data for omecamtiv mecarbil at AHA show a slim overall benefit, but Cytokinetics highlighted its effects in sicker patients and investigators emphasized the drug’s impact on reduced hospitalizations.

Clinical Trials Cardiovascular

Kite’s Tecartus PRIMEd For EU Market With CHMP Nod

Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.

Approvals Companies

J&J, Acutus And Boston Scientific Announce Plans For Pulsed Field AF-Ablation Technologies

Pulsed field ablation, which uses a controlled electrical field instead of focused heat or cold, has shown promise as a safer alternative to thermal and cryo approaches for atrial fibrillation ablation.

Clinical Trials Research & Development
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • DOV Pharmaceutical, Inc.
UsernamePublicRestriction

Register